In line with this observation, we found that targeting TKT significantly reduced FBXL6-mediated PD-L1 expression and blocked HCC tumorigenesis and metastasis, suggesting TKT as a potential therapeutic target for patients with FBXL6-high HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.